Kbc Group Nv Janux Therapeutics, Inc. Transaction History
Kbc Group Nv
- $37 Billion
- Q2 2025
A detailed history of Kbc Group Nv transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Kbc Group Nv holds 1,387 shares of JANX stock, worth $37,324. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,387
Previous 2,461
43.64%
Holding current value
$37,324
Previous $66,000
51.52%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding JANX
# of Institutions
188Shares Held
56MCall Options Held
869KPut Options Held
652K-
Ra Capital Management, L.P. Boston, MA11.2MShares$301 Million5.65% of portfolio
-
Janus Henderson Group PLC London, X04.46MShares$120 Million0.05% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.92MShares$78.6 Million3.15% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.53MShares$67.9 Million0.1% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$63.1 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.12B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...